Company / SG&A Expense
Compass Therapeutics, Inc. SG&A Expense History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$15.1M
FY2024
5-year range
$10.9M / $15.1M
FY2020-FY2024
Trend
+23.6%
vs FY2023
Sector context
#205 of 213
Health Care
What the data says
Among 213 Health Care companies, Compass Therapeutics, Inc. is in the top 4% for sg&a expense. SG&A Expense has increased for 3 consecutive years, from $11M in FY2021 to $15M in FY2024.
Based on SEC 10-K filings.
$15M in FY2024 with a 5-year CAGR of +5.5%.
Increased from $12M to $15M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +11.5%
- 5-Year CAGR
- +5.5%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 213This company $15.1M Sector average $722.3M
▼
-97.9% below sector average
Key checks
Key Insights
- Compass Therapeutics, Inc.'s sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +5.5%, indicating consistent growth.
- In FY2024, sg&a expense increased 23.6% year-over-year.
- Ranks #205 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $15.1M | +23.6% |
| FY2023 | $12.2M | +5.0% |
| FY2022 | $11.7M | +6.7% |
| FY2021 | $10.9M | -15.3% |
| FY2020 | $12.9M | +11.2% |
| FY2019 | $11.6M | +35319.3% |
| FY2018 | $32.8K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026